# A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Source: https://onco.cc/trials/nct07318558/  
OnCo record `nct07318558` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sacituzumab tirumotecan, Bevacizumab in ovarian cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) is a phase 3 interventional study registered as NCT07318558 by Merck Sharp & Dohme LLC, with 900 participants planned, started 2026-02-16 and due to reach its primary completion in 2033-02-25. Interventions recorded: Sacituzumab tirumotecan, Bevacizumab, Rescue Medications. Conditions listed: Ovarian Neoplasms, Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07318558
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 900

## Sources

- ClinicalTrials.gov NCT07318558: https://clinicaltrials.gov/study/NCT07318558

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07318558.json